New mRNA flu vaccine shows promise in early human trial
NCT ID NCT06602531
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tested a new self-amplifying mRNA vaccine (ARCT-2304) designed to protect against pandemic influenza. 212 healthy adults aged 18-80 received either two doses of the experimental vaccine or one dose of a licensed flu vaccine plus placebo. Researchers monitored safety and immune responses to find the best dose and schedule for future studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Self-amplifying mRNA pandemic influenza vaccine (ARCT-2304)
What this could lead to
If successful, this could lead to a faster, more effective vaccine against pandemic influenza strains.
What could go wrong
This is an early phase 1 trial with only 212 participants, so safety and immune response are still being explored. The vaccine may not produce strong enough immunity or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA, HUMAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CTI Clinical Research Center
Cincinnati, Ohio, 45212, United States
-
Tekton Research
Longmont, Colorado, 80501, United States
-
Velocity Clinical Research
La Mesa, California, 91942, United States
-
Velocity Clinical Research
San Bernardino, California, 92408, United States